As­traZeneca, Am­gen whip up some block­buster ex­cite­ment with a pos­si­ble game-chang­ing asth­ma drug

As­traZeneca and Am­gen rolled out Phase IIb da­ta on their late-stage drug teze­pelum­ab late on Wednes­day, spot­light­ing some dra­mat­ic re­sults for a ther­a­py they be­lieve could have megablock­buster po­ten­tial for the broad-based treat­ment of un­con­trolled asth­ma.

Bot­tom line: Treat­ment-re­sis­tant pa­tients in the drug arm tak­ing a med­ley of dos­es saw their an­nu­al ex­ac­er­ba­tion rate slashed any­where from 61% to 71%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.